Form 4 for CRL Charles River Laboratories
Accepted 2024-06-03 00:00:00 ET · period of report 2024-05-31 · accession 0001127602-24-017309 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-03 | 2024-05-31 | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | A - Grant | $0.00 | +2,111 | 24.6K | +9% | $0 |
| D | 2024-06-03 | 2024-05-31 | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | A - Grant | $208.44 | +4,797 | 4,797 | New | +$999.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-31 | A | A | 2,111 | $0.00 | 24,612 | D | — | — | (F1) Unvested restricted stock units vest as follows: 527 on May 31, 2025, 528 on May 31, 2026, 528 on May 31, 2027, and 528 on May 31, 2028. |
| 2 | Derivative | Stock Options (Right to Buy) | 2024-05-31 | A | A | 4,797 | $208.44 | 4,797 | D | $208.44 · 2025-05-31 to 2034-05-31 | 4,797 Common Stock | (F2) Stock options vest as follows: 1,199 on May 31, 2025, 1,199 on May 31, 2026, 1,199 on May 31, 2027, and 1,200 on May 31, 2028. |